UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATIONShare Purchase Agreement • December 12th, 2022 • Sunshine Biopharma, Inc • Services-commercial physical & biological research
Contract Type FiledDecember 12th, 2022 Company IndustryEffective October 20, 2022, Sunshine Biopharma, Inc. (“Sunshine” or the “Company”) entered into a Share Purchase Agreement with Nora Pharma Inc. (the “Nora Purchase Agreement”), wherein the Company acquired all of the issued and outstanding shares (the “Shares”) of Nora Pharma Inc. (“Nora”) from Mr. Malek Chamoun. The purchase price for the Shares was $30,000,000 CAD (approximately $21,900,000 USD). The purchase price included a cash payment of $20,000,000 CAD (approximately $14,600,000 USD), plus issuance of 3,700,000 shares of the Company’s Common Stock valued at $5,000,000 CAD (approximately $3,650,000 USD), plus an earn-out amount of $5,000,000 CAD (approximately $3,650,000 USD) payable to Mr. Chamoun, once earned, in a maximum of twenty (20) payments of $250,000 CAD for every $1,000,000 CAD increase in gross sales (as defined in the Nora Purchase Agreement) above Nora’s June 30, 2022 gross sales, provided that his employment with the Company is not terminated pursuant to the Compa
Share Purchase Agreement between Q-Cells SE and Renewable Energy Corporation ASA and Evergreen Solar, Inc. and Rolling Hills S.à r.l. dated 22 March 2010 regarding the sale and purchase of Sovello AGShare Purchase Agreement • September 14th, 2010 • Evergreen Solar Inc • Semiconductors & related devices
Contract Type FiledSeptember 14th, 2010 Company Industry